Can heparin prevent adverse pregnancy outcome?

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 12, Issue 1, 2002, Pages 1-8

  Romero, Roberto ^a   Dekker, G ^a   Kupferminc, M ^a   Saade, G ^a   Livingston, J ^a   Peaceman, A ^a   Mazor, M ^a   Yoon, B H ^a   Espinoza, J ^a   Chaiworapongsa, T ^a   Gomez, R ^a   Arias, F ^a   Sibai, B ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; ANTICOAGULANT AGENT;

DISEASE ASSOCIATION; EDITORIAL; FETUS MORTALITY; FIBRINOLYSIS; HEMOSTASIS; HUMAN; INTRAUTERINE GROWTH RETARDATION; PLACENTA CIRCULATION; PREECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATION; PRIORITY JOURNAL; PROPHYLAXIS; THROMBOSIS; FEMALE; PREGNANCY OUTCOME; THROMBOEMBOLISM;

ANTICOAGULANTS; FEMALE; HEPARIN; HUMANS; PLACENTAL CIRCULATION; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PREGNANCY OUTCOME; THROMBOEMBOLISM;

EID: 0035988789     PISSN: 14767058     EISSN: None     Source Type: Journal    
DOI: 10.1080/jmf.12.1.1.8     Document Type: Editorial

References (126)

1. The child is the father of the man
2. Anti-platelet drugs for prevention of pre-eclampsia and its consequences
3. A meta-analysis of low dose aspirin for the prevention of intrauterine growth retardation
4. Endothelial dysfunction in preeclampsia
5. The management of acquired hemostasis failure during pregnancy
6. The physiology of menstruation
7. Decidual cell-expressed tissue factor maintains hemostasis in human endometrium
8. The decidua regulates hemostasis in human endometrium
9. Morphology of menstrual hemostasis in essential menorrhagia
10. Coagulation and fibrinolytic parameters in normal pregnancy and in pregnancy complicated by intrauterine growth retardation
11. Fibrinopeptide A during normal pregnancy
12. Enhanced thrombin generation in normal and hypertensive pregnancy
13. Changes in the blood coagulation and fibrinolysis system in the course of normal pregnancy
14. Perturbed (procoagulant) endothelium and deviations within the fibrinolytic system during the third trimester of normal pregnancy. A possible link to placental function
15. Changes in activated protein C resistance during normal pregnancy
16. Plasma antithrombin III activity in normal pregnancy
17. Fibrinopeptide A levels in maternal and newborn plasma
18. Fibrinopeptide A during normal pregnancy
19. Increased thrombin generation in normal pregnancy
20. Fibrin generation in normal pregnancy
21. Endothelial cell markers and fibrinopeptide A to D-dimer ratio as a measure of coagulation and fibrinolysis balance in normal pregnancy
22. Activation of coagulation system in preterm labor and preterm premature rupture of membranes
23. Mechanisms involved in agonist-induced hyperaggregability of platelets from normal pregnancy
24. The hyperaggregability of platelets from normal pregnancy is mediated through thromboxane A2 and cyclic AMP pathways
25. Plasma adenosine levels increase in women with normal pregnancies
26. Beta-thromboglobulin during normal pregnancy, labor, and puerperium
27. Longitudinal analysis of platelet count and volume in normal pregnancy
28. Placental histology and clinical characteristics of patients with preterm premature rupture of membranes
29. Placental thrombi and other vascular lesions. Classification, morphology, and clinical correlations
30. Maternal placental vasculopathy and infection: Two distinct subgroups among patients with preterm labor and preterm ruptured membranes
31. Abruptio placentae. A 'classic' dedicated to Elizabeth Ramsey
32. Placental pathologic features of preterm preeclampsia
33. Intrauterine growth restriction in infants of less than thirty-two weeks' gestation: Associated placental pathologic features
34. Placental bed biopsies in placental abruption
35. Doppler blood flow changes and placental morphology in pregnancies with third trimester hemorrhage
36. Pathology of intrauterine growth retardation
37. Thrombophilia: A mechanism of disease in women with adverse pregnancy outcome and thrombotic lesions in the placenta
38. Do placental lesions reflect thrombophilia state in women with adverse pregnancy outcome?
39. Placental pathology in early onset pre-eclampsia and intra-uterine growth restriction in women with and without thrombophilia
40. Adriana and Luisa Castellucci Award Lecture 1997. Placental pathology in obstetrics: Adaptation or failure of the villous tree?
41. Endothelial cell dysfunction in preeclampsia
42. Extensive platelet activation in preeclampsia compared with normal pregnancy: Enhanced expression of cell adhesion molecules
43. Plasma P selectin (GMP-140) and glycocalicin are elevated in pre-eclampsia and eclampsia: Their significances
44. Whole blood platelet aggregation in moderate and severe pre-eclampsia
45. Markers for endothelial injury, clotting and platelet activation in pre-eclampsia
46. Haemostatic and rheological changes in normal pregnancy and pre-eclampsia
47. Beta-thromboglobulin in pre-eclampsia
48. Platelets and the beginnings of pre-eclampsia
49. Early platelet consumption in pre-eclampsia
50. Clinical significance, prevalence and natural history of thrombocytopenia in pregnancy induced hypertension
51. Plasma-beta-thromboglobulin in pre-eclampsia
52. Clinical use of beta-thromboglobulin levels in diagnosing and treating consumptive and immune thrombocytopenia
53. Plasma beta-thromboglobulin: Differentiation between intravascular and extravascular platelet destruction
54. Plasma levels of beta-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo
55. Plasma fibrinopeptide A and beta-thromboglobulin in pre-eclampsia and pregnancy hypertension
56. Serotonin in toxaemia of pregnancy
57. Toxemia: New concepts in an old disease
58. Platelet indices during normal pregnancy and pre-eclampsia
59. Antepartum reversal of hematologic abnormalities associated with the HELLP syndrome. A report of three cases
60. Coagulation and fibrinolytic systems in pre-eclampsia and eclampsia
61. Coagulation studies in the hypertensive toxemias of pregnancy
62. Hematologic assays in pre-eclampsia
63. Clinical relevance of coagulation and renal changes in pre-eclampsia
64. Thrombocytopenia and macro-thrombocytosis in gestational hypertension
65. Blood coagulation profile in patients with acute diffuse peritonitis
66. Platelets and intrauterine growth retardation in pre-eclampsia
67. A platelet function defect in preeclampsia
68. Thrombocytopenia in obstetric syndromes. A review
69. Possible role of 5-hydroxytryptamine in toxaemia of pregnancy
70. The role of serotonin in the preeclampsia-eclampsia syndrome
71. Abnormal platelet function in pre-eclampsia
72. Inhibition of platelet aggregation by placental extracts
73. Pregnancy, pre-eclampsia and disseminated intravascular coagulation
74. Blood coagulation and toxemia of pregnancy
75. The relevance of intravascular coagulation to pre-eclampsia
76. Coagulation, fibrinolysis and platelet function in pre-eclampsia, essential hypertension and placental insufficiency
77. Abnormal hemostasis and coagulopathy in preeclampsia and eclampsia
78. On the pathogenesis of pre-eclampsia and eclampsia
79. Hematologic evidence of disseminated intravascular coagulation in eclampsia
80. Fibrinopeptide A and beta-thromboglobulin levels in preeclampsia and hypertensive pregnancy
81. Preeclampsia as chronic disseminated intravascular coagulation. Study of two parameters: Thrombin-antithrombin III complex and D-dimers
82. Review of antithrombin III; evidence that antithrombin III is the main physiological inhibitor of coagulation enzymes
83. Antithrombin III(AT-III) as a diagnostic aid in disseminated intravascular coagulation
84. Antithrombin III levels in normotensive and hypertensive pregnancy
85. Evidence of in vivo generation of thrombin in patients with small for gestational age fetuses and pre-eclampsia
86. Hemostasis in the uteroplacental and peripheral circulations in normotensive and pre-eclamptic pregnancies
87. Pathogenesis of thrombosis
88. Fibrinolytic activity and protein C in preeclampsia
89. The fast inhibitor of tissue plasminogen activator in plasma during pregnancy
90. Plasma antithrombin III activity: An aid in the diagnosis of preeclampsia-eclampsia
91. Clotting alterations associated with the pre-eclampsia/eclampsia syndrome
92. Placental-type plasminogen activator inhibitor in preeclampsia
93. Clinical and haemostatic parameters in the HELLP syndrome: Relevance of plasminogen activator inhibitors
94. Fibrinolytic system and reproductive process with special reference to fibrinolytic failure in pre-eclampsia
95. Genetic hypofibrinolysis in complicated pregnancies
96. Coagulation/fibrinolysis disorder in patients with severe pre-eclampsia
97. Markers of intravascular coagulation and fibrinolysis in preeclampsia: Association with intrauterine growth retardation
98. Plasma fibrinolytic activity in pregnancy with particular reference to pre-eclampsia
99. Early detection of preeclampsia by determination of platelet aggregability
100. Can flow cytometric detection of platelet activation early in pregnancy predict the occurrence of preeclampsia? A prospective study
101. Decreased prostacyclin production by placental cells in culture from pregnancies complicated by fetal growth retardation
102. Prostacyclin and pre-eclampsia
103. Low-dose aspirin: Treatment for the imbalance of increased thromboxane and decreased prostacyclin in preeclampsia
104. Preeclampsia: An imbalance in placental prostacyclin and thromboxane production
105. Plasma levels of thrombin-antithrombin complexes predict preterm premature rupture of the fetal membranes
106. Increased thrombin generation in women with recurrent miscarriage
107. Inherited thrombophilia and pregnancy: The obstetric perspective
108. Underlying disorders associated with severe early-onset preeclampsia
109. Inherited thrombophilias: Indications for pregnancy-associated venous thromboembolism and obstetric complications
110. Inherited thrombophilias in pregnant patients: Detection and treatment paradigm
111. Third-trimester unexplained intrauterine fetal death is associated with inherited thrombophilia
112. Increased frequency of genetic thrombophilia in women with complications of pregnancy
113. How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review
114. High prevalence of hemostatic abnormalities in women with a history of severe pre-eclampsia
115. Fetal carriers of the factor V Leiden mutation are prone to miscarriage and placental infarction
116. Long term mortality of mothers and fathers after pre-eclampsia: Population based cohort study
117. Pre-eclampsia and cardiovascular disease later in life: Who is at risk?
118. Mutations in coagulation factors in women with unexplained late fetal loss
119. Pathologic features of the placenta in women with severe pregnancy complications and thrombophilia
120. Prevention of preeclampsia with heparin and antiplatelet drugs in women with renal disease
121. Antiphospholipid antibody-associated recurrent pregnancy loss: Treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone
122. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies)
123. Low-molecular-weight heparin for the prevention of obstetric complications in women with thrombophilias
124. Thromboprophylaxis in pregnancy reduces fetal losses in women with heritable thrombophila: A prospective EPCOT study
125. Low-molecular-weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: A preliminary study